DK3805248T5 - Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf - Google Patents

Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf Download PDF

Info

Publication number
DK3805248T5
DK3805248T5 DK20200642.5T DK20200642T DK3805248T5 DK 3805248 T5 DK3805248 T5 DK 3805248T5 DK 20200642 T DK20200642 T DK 20200642T DK 3805248 T5 DK3805248 T5 DK 3805248T5
Authority
DK
Denmark
Prior art keywords
antibodies
procedure
concentration
therapeutic products
therapeutic
Prior art date
Application number
DK20200642.5T
Other languages
English (en)
Other versions
DK3805248T3 (da
Inventor
Charles Matthew Winter
Original Assignee
Novartis Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3805248(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Genentech Inc filed Critical Novartis Ag
Publication of DK3805248T3 publication Critical patent/DK3805248T3/da
Application granted granted Critical
Publication of DK3805248T5 publication Critical patent/DK3805248T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DK20200642.5T 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf DK3805248T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
EP10009914.2A EP2292636B9 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof

Publications (2)

Publication Number Publication Date
DK3805248T3 DK3805248T3 (da) 2023-04-03
DK3805248T5 true DK3805248T5 (da) 2023-04-24

Family

ID=35996499

Family Applications (5)

Application Number Title Priority Date Filing Date
DK05806393.4T DK1786830T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til koncentration af antistoffer og terapeutiske produkter deraf
DK22178117.2T DK4108259T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK20200642.5T DK3805248T5 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK10009914.2T DK2292636T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK22178156.0T DK4104859T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK05806393.4T DK1786830T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til koncentration af antistoffer og terapeutiske produkter deraf
DK22178117.2T DK4108259T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10009914.2T DK2292636T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK22178156.0T DK4104859T3 (da) 2004-09-09 2005-09-08 Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf

Country Status (33)

Country Link
US (6) US20060051347A1 (da)
EP (5) EP4108259B1 (da)
JP (2) JP5210633B2 (da)
KR (2) KR101528970B1 (da)
CN (3) CN101056885B (da)
AR (1) AR050641A1 (da)
AU (1) AU2005285243C1 (da)
BR (1) BRPI0515649B8 (da)
CA (1) CA2577317C (da)
DK (5) DK1786830T3 (da)
EC (1) ECSP077282A (da)
ES (4) ES2975166T3 (da)
FI (3) FI2292636T3 (da)
GT (1) GT200500254A (da)
HK (2) HK1101249A1 (da)
HU (2) HUE065025T2 (da)
IL (2) IL181372A (da)
LT (4) LT4104859T (da)
MA (1) MA28991B1 (da)
MX (2) MX2007002812A (da)
MY (2) MY162525A (da)
NO (1) NO333660B1 (da)
NZ (1) NZ553239A (da)
PE (1) PE20060816A1 (da)
PL (4) PL3805248T3 (da)
PT (4) PT2292636T (da)
RU (1) RU2390524C2 (da)
SG (1) SG177161A1 (da)
SI (4) SI2292636T1 (da)
TN (1) TNSN07069A1 (da)
TW (1) TWI372630B (da)
WO (1) WO2006031560A2 (da)
ZA (1) ZA200701626B (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
MXPA06012990A (es) 2004-05-12 2007-02-12 Baxter Int Microesferas de acidos nucleicos, produccion y suministro de las mismas.
JP2007537288A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
EP2583744A1 (en) * 2006-03-31 2013-04-24 Genencor International, Inc. Permeate product of tangential flow filtration process
ES2744499T3 (es) 2006-04-04 2020-02-25 Chiesi Farm Spa Un proceso para la concentración de un polipéptido
EP2527364A1 (en) 2007-03-29 2012-11-28 Abbott Laboratories Crystalline anti-human IL-12 antibodies
WO2009010269A1 (en) 2007-07-17 2009-01-22 F.Hoffmann-La Roche Ag Variable tangential flow filtration
WO2009068282A1 (en) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Immunoglobulin aggregates
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI661833B (zh) * 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
NZ589297A (en) * 2008-05-15 2011-12-22 Health L P W Process for producing milk fractions rich in secretory immunoglobulins
US20110236391A1 (en) * 2008-12-09 2011-09-29 Hanns-Christian Mahler Method for obtaining an excipient-free antibody solution
WO2010090864A2 (en) * 2009-01-21 2010-08-12 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
US9586180B2 (en) * 2009-03-24 2017-03-07 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
MY157239A (en) 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
JP5697268B2 (ja) * 2009-09-29 2015-04-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ バッファー溶質のろ過前調整方法
EP3715369A1 (en) * 2009-10-01 2020-09-30 F. Hoffmann-La Roche AG Multistep final filtration
KR101912169B1 (ko) 2010-02-04 2018-10-26 체에스엘 베링 아게 면역글로불린 제제
CA2976671C (en) 2010-03-01 2021-01-12 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
KR101993488B1 (ko) 2011-09-01 2019-06-26 추가이 세이야쿠 가부시키가이샤 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP2016504344A (ja) * 2012-12-28 2016-02-12 ノヴォ ノルディスク アー／エス 高温デッドエンド抗体ろ過
JP6427502B2 (ja) 2013-01-09 2018-11-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａの精製方法
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
CN106794424B (zh) 2014-05-13 2020-10-30 美国安进公司 用于过滤器和过滤过程的过程控制系统和方法
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
WO2015195453A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
WO2015195452A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Single-pass filtration systems and processes
JP6339674B2 (ja) 2014-06-25 2018-06-06 イー・エム・デイー・ミリポア・コーポレイシヨン 小型スパイラル型フィルターエレメント、モジュール、およびシステム
SG11201508665QA (en) 2014-08-29 2016-03-30 Emd Millipore Corp Processes For Filtering Liquids Using Single Pass Tangential Flow Filtration Systems AndTangential Flow Filtration Systems With Recirculation of Retentate
WO2016033546A1 (en) 2014-08-29 2016-03-03 Emd Millipore Corporation Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
CN107206070B (zh) 2014-10-23 2022-01-18 美国安进公司 降低药物制剂的粘度
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CA2999118C (en) * 2015-09-22 2022-06-14 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
JP7106523B2 (ja) * 2016-08-16 2022-07-26 ジェンザイム・コーポレーション 組換え治療用タンパク質を含む流体を処理する方法およびその使用
EP3500588A1 (en) * 2016-08-17 2019-06-26 Boehringer Ingelheim International GmbH Process for the preparation of highly concentrated liquid formulations containing biomolecules
EA201990998A1 (ru) 2016-10-21 2019-11-29 Фармацевтические составы и способы их получения
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
KR20190079530A (ko) * 2017-12-27 2019-07-05 (주)셀트리온 투석 여과 방법
AU2019250882A1 (en) * 2018-04-12 2020-11-05 Amgen Inc. Methods for making stable protein compositions
WO2019213567A1 (en) * 2018-05-04 2019-11-07 Genzyme Corporation Perfusion bioreactor with filtration systems
US20210308265A1 (en) * 2018-08-10 2021-10-07 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
US20210171573A1 (en) * 2018-08-14 2021-06-10 Bristol-Myers Squibb Company Improved protein recovery
TW202043253A (zh) * 2019-01-28 2020-12-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
PT3791395T (pt) * 2019-07-31 2021-09-22 Catalent Uk Swindon Zydis Ltd Medidor de fluxo de densidade para dosagem de formulação farmacêutica
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
EP4225770A1 (en) * 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Methods for concentrating proteins
AU2021381439A1 (en) 2020-11-23 2023-06-22 Abec, Inc. Filtration systems,components and methods
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
TW202342068A (zh) 2022-02-25 2023-11-01 美商安進公司 製備高濃度液體原料藥之方法
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
WO2024012364A1 (en) * 2022-07-12 2024-01-18 Beigene Switzerland Gmbh Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (da) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IN161706B (da) * 1983-10-05 1988-01-16 Solco Basel Ag
US4786501A (en) 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CN102416176A (zh) * 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
KR20010030665A (ko) 1997-09-22 2001-04-16 세프라겐 코포레이션 유장 단백질의 순차적 분리법 및 그의 제제
RU2140287C1 (ru) 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
WO2000024266A2 (en) 1998-10-26 2000-05-04 Galagen, Inc. Soy and immunoglobulin compositions
UY26236A1 (es) 1999-07-07 2000-10-31 New Zeland Co Operative Dairy Metodos para obtener aislados de proteina y concentrados de calostro
AU2001277781A1 (en) * 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
ES2351786T3 (es) * 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
JP4500683B2 (ja) * 2002-11-01 2010-07-14 バイエル・ヘルスケア・エルエルシー 巨大分子濃縮方法
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
JP2006515227A (ja) * 2003-02-24 2006-05-25 ジーティーシー バイオセラピューティックス インコーポレイテッド 十字流濾過の方法およびそのための装置
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法

Also Published As

Publication number Publication date
SI4108259T1 (sl) 2024-04-30
DK2292636T3 (da) 2024-01-15
EP4108259B1 (en) 2024-01-03
FI3805248T3 (fi) 2023-04-21
MX342788B (es) 2016-10-12
EP4104859A1 (en) 2022-12-21
PT2292636T (pt) 2024-01-09
US11767370B2 (en) 2023-09-26
KR20120135530A (ko) 2012-12-14
US20140370003A1 (en) 2014-12-18
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
US20090214522A1 (en) 2009-08-27
SI2292636T1 (sl) 2024-02-29
IL216851A0 (en) 2012-01-31
CN101056885B (zh) 2015-08-26
US20210095050A1 (en) 2021-04-01
US20070237762A1 (en) 2007-10-11
KR101528970B1 (ko) 2015-06-15
PL1786830T3 (pl) 2015-05-29
EP3805248B1 (en) 2023-01-18
EP1786830A2 (en) 2007-05-23
AU2005285243B2 (en) 2012-03-08
EP2292636A3 (en) 2013-05-01
EP2292636B1 (en) 2023-10-18
EP2292636B9 (en) 2024-01-03
JP5210633B2 (ja) 2013-06-12
PL4108259T3 (pl) 2024-05-13
NZ553239A (en) 2009-11-27
US10370456B2 (en) 2019-08-06
ES2942574T3 (es) 2023-06-02
US20060051347A1 (en) 2006-03-09
JP2008512473A (ja) 2008-04-24
MX2007002812A (es) 2007-05-16
BRPI0515649A (pt) 2008-07-29
MY162525A (en) 2017-06-15
DK1786830T3 (da) 2015-01-19
ES2968070T3 (es) 2024-05-07
CA2577317C (en) 2016-04-26
SI3805248T1 (sl) 2023-05-31
AR050641A1 (es) 2006-11-08
PT1786830E (pt) 2015-02-05
DK4104859T3 (da) 2024-07-08
NO333660B1 (no) 2013-08-05
TWI372630B (en) 2012-09-21
CN102911268A (zh) 2013-02-06
PT3805248T (pt) 2023-04-05
PE20060816A1 (es) 2006-09-02
MA28991B1 (fr) 2007-11-01
ECSP077282A (es) 2007-03-29
HUE061899T2 (hu) 2023-08-28
IL181372A0 (en) 2007-07-04
LT4104859T (lt) 2024-07-10
CN101056885A (zh) 2007-10-17
DK3805248T3 (da) 2023-04-03
CA2577317A1 (en) 2006-03-23
EP2292636A2 (en) 2011-03-09
ES2975166T3 (es) 2024-07-03
BRPI0515649B8 (pt) 2021-11-03
EP1786830B1 (en) 2014-11-12
NO20071432L (no) 2007-03-16
CN104961797B (zh) 2020-12-25
JP5426641B2 (ja) 2014-02-26
EP4104859B1 (en) 2024-04-17
SG177161A1 (en) 2012-01-30
EP4108259A1 (en) 2022-12-28
PL3805248T3 (pl) 2023-05-22
CN104961797A (zh) 2015-10-07
HK1101249A1 (en) 2007-10-12
BRPI0515649B1 (pt) 2021-10-13
AU2005285243C1 (en) 2012-10-25
PL2292636T3 (pl) 2024-03-11
FI4104859T3 (fi) 2024-07-16
IL181372A (en) 2012-01-31
PT4108259T (pt) 2024-03-07
WO2006031560A3 (en) 2006-08-24
DK4108259T3 (da) 2024-03-11
FI2292636T3 (fi) 2024-01-12
HK1215869A1 (zh) 2016-09-23
KR20070109975A (ko) 2007-11-15
RU2390524C2 (ru) 2010-05-27
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
ES2528541T3 (es) 2015-02-10
KR101528970B9 (ko) 2022-12-09
JP2012097086A (ja) 2012-05-24
ZA200701626B (en) 2008-10-29
SI1786830T1 (sl) 2015-03-31
US20230074486A1 (en) 2023-03-09
TW200612989A (en) 2006-05-01
HUE065025T2 (hu) 2024-04-28
LT4108259T (lt) 2024-04-10
AU2005285243A1 (en) 2006-03-23
TNSN07069A1 (en) 2008-06-02
WO2006031560A2 (en) 2006-03-23
EP3805248A3 (en) 2021-07-14
LT3805248T (lt) 2023-04-25
MY150549A (en) 2014-01-30

Similar Documents

Publication Publication Date Title
DK2292636T3 (da) Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK3345927T3 (da) Humant monoklonalt antistof Human CD134 (OX40) og fremgangsmåder til frembringelse og anvendelse deraf
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1679058T3 (da) Farmaceutisk sammensætning til behandling af kardiovaskulære og cerebrovaskulære sygdomme
DK1756544T3 (da) Diagnoseindretninger indeholdende fluider og fremgangsmåder til fremstilling
DK1641832T3 (da) Fremgangsmåde til fremstilling af fiberholdig pektin og produkter og anvendelser heraf
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
DK1844074T3 (da) Humane antistoffer og proteiner
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DK1740197T3 (da) Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki
DK1755743T3 (da) Beta-hydroxybutyrat og derivater til behandling af depression og angst
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1965763T3 (da) Stabile enzympræparater og fremgangsmåder til anvendelse heraf
DK1663298T3 (da) Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner
DK1877090T3 (da) Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
DK1862158T5 (da) Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
DK1919290T3 (da) Fremgangsmåder og produkter til behandling af sygdomme
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
DK2144555T4 (da) Indretning og fremgangsmåde til transkutan bestemmelse af blodgasser
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
DK1788881T3 (da) Fremgangsmåder og produkter til brødfremstilling